AMGNライブシグナル | Getagraph.comで利益を最大化

売る 652 min ago

@ $311.75

発行日: 29 6月 2024 @ 04:27

リターン: 0.22%

前回のシグナル: 6月 29 - 03:39

前回のシグナル: 買う

リターン: 0.02 %

Live Chart Being Loaded With Signals

Commentary (29 6月 2024 @ 05:00):
Our systems believe the stock currently is overvalued by -0.40% compare to its pairs and should correct downwards.

Stats
本日の出来高	3.51M
平均出来高	2.53M
時価総額	167.61B
EPS	$-0.210 ( Q1 \| 2024-05-03 )
次の収益日	( $4.86 ) 2024-08-01
Last Dividend	$2.25 ( 2024-05-16 )
Next Dividend	$0 ( N/A )
P/E	44.64 (Sector) 42.63 (Industry) 0
ATR14	$6.07 (1.94%)

AMGN -0.40%

BIIB 1.36%

GILD -0.32%

GRFS 0.08%

HZNP 0.00%

SNY 0.92%

Insider Trading

Date	Person	Action	Amount	type
2024-05-31	Miles Amy E	Buy	719	Common Stock
2024-05-31	Kullman Ellen Jamison	Buy	719	Common Stock
2024-05-31	Klotman Mary E.	Buy	719	Common Stock
2024-05-31	Jacks Tyler	Buy	719	Common Stock
2024-05-31	Ishrak Omar	Buy	719	Common Stock

INSIDER POWER
65.34
Last 98 transactions
Buy: 382 825 \| Sell: 84 958

相関 (AI algo v.1.1b): Overvalued: -0.40% $313.88 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.20 (neutral)

短: -0.81 (strong negative)

Signal:(60) Neutral

Amgen Inc 相関

10 最も正の相関
OZEM	1
PODC	0.896
QREARX	0.881
IIMFX	0.88
BAER	0.879
GBLMX	0.877
KYTX	0.874
AONC	0.874
NTRP	0.874
GXAI	0.871

10 最も負の相関
MAMA	-0.921
NBBK	-0.921
HLP	-0.912
SAIA	-0.903
MCAAW	-0.898
IBTA	-0.893
PLAO	-0.893
ICTVX	-0.893
EVCGX	-0.89
DFLI	-0.888

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Amgen Inc 相関 - 通貨/商品

0.33
( neutral )

0.44
( neutral )

0.00
( neutral )

-0.83
( strong negative )

-0.25
( neutral )

-0.40
( neutral )

Amgen Inc 財務諸表

Annual	2023
収益:	$28.19B
総利益:	$19.74B (70.02 %)
EPS:	$12.56

FY	2023
収益:	$28.19B
総利益:	$19.74B (70.02 %)
EPS:	$12.56

FY	2022
収益:	$26.32B
総利益:	$19.92B (75.66 %)
EPS:	$12.18

FY	2021
収益:	$25.98B
総利益:	$19.53B (75.16 %)
EPS:	$10.06

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.940 (N/A)	$1.940 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.25 (N/A)	$2.25 (N/A)	$0 (N/A)	$0 (N/A)

Amgen Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.12 - Increase likely (42.31%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2011-08-16
Last Dividend	$2.25	2024-05-16
Next Dividend	$0	N/A
Payout Date	2024-06-07
Next Payout Date	N/A
# dividends	52	--
Total Paid Out	$63.38	--
Avg. Dividend % Per Year	2.65%	--
Score	5.72	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.12
Div. Directional Score	8.79	--

Next Divdend (Est)
(2024-07-01)

$2.29 Estimate 74.39 %

Dividend Stability

0.99 Excellent

Dividend Score

5.72

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0.560	1.01%
2012	$1.440	2.25%
2013	$1.880	2.11%
2014	$2.44	2.11%
2015	$3.16	1.98%
2016	$4.00	2.53%
2017	$4.60	3.05%
2018	$5.28	2.98%
2019	$5.80	3.02%
2020	$6.40	2.67%
2021	$7.04	3.11%
2022	$7.76	3.42%
2023	$8.52	3.26%
2024	$4.50	1.51%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
16 May 2024	$2.25	06 Mar 2024	17 May 2024	07 Jun 2024
15 Feb 2024	$2.25	12 Dec 2023	16 Feb 2024	07 Mar 2024
16 Nov 2023	$2.13	24 Oct 2023	17 Nov 2023	08 Dec 2023
17 Aug 2023	$2.13	01 Aug 2023	18 Aug 2023	08 Sep 2023
17 May 2023	$2.13	07 Mar 2023	18 May 2023	08 Jun 2023
14 Feb 2023	$2.13	12 Dec 2022	15 Feb 2023	08 Mar 2023
16 Nov 2022	$1.940	28 Oct 2022	17 Nov 2022	08 Dec 2022
17 Aug 2022	$1.940	03 Aug 2022	18 Aug 2022	08 Sep 2022
16 May 2022	$1.940	02 Mar 2022	17 May 2022	08 Jun 2022
14 Feb 2022	$1.940	03 Dec 2021	15 Feb 2022	08 Mar 2022
15 Nov 2021	$1.760	21 Oct 2021	16 Nov 2021	08 Dec 2021
16 Aug 2021	$1.760	30 Jul 2021	17 Aug 2021	08 Sep 2021
14 May 2021	$1.760	03 Mar 2021	17 May 2021	08 Jun 2021
11 Feb 2021	$1.760	16 Dec 2020	15 Feb 2021	08 Mar 2021
13 Nov 2020	$1.600	21 Oct 2020	16 Nov 2020	08 Dec 2020
14 Aug 2020	$1.600	23 Jul 2020	17 Aug 2020	08 Sep 2020
15 May 2020	$1.600	04 Mar 2020	18 May 2020	08 Jun 2020
13 Feb 2020	$1.600	11 Dec 2019	14 Feb 2020	06 Mar 2020
14 Nov 2019	$1.450	22 Oct 2019	15 Nov 2019	06 Dec 2019
14 Aug 2019	$1.450	02 Aug 2019	15 Aug 2019	06 Sep 2019

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.128	1.500	7.45	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0405	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.586	1.500	4.60	6.90	[0.1 - 1]
payoutRatioTTM	1.230	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.422	0.800	7.89	6.31	[1 - 3]
quickRatioTTM	0.836	0.800	9.79	7.83	[0.8 - 2.5]
cashRatioTTM	0.492	1.500	8.38	10.00	[0.2 - 2]
debtRatioTTM	0.689	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.299	-0.299	[3 - 30]
operatingCashFlowPerShareTTM	15.10	2.00	4.97	9.93	[0 - 30]
freeCashFlowPerShareTTM	13.24	2.00	3.38	6.76	[0 - 20]
debtEquityRatioTTM	12.75	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.663	1.000	2.28	2.28	[0.2 - 0.8]
operatingProfitMarginTTM	0.235	1.000	7.31	7.31	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.126	1.000	-0.409	-0.409	[0.2 - 2]
assetTurnoverTTM	0.317	0.800	-1.220	-0.976	[0.5 - 2]
Total Score				10.46

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	44.68	1.000	5.59	0	[1 - 100]
returnOnEquityTTM	0.586	2.50	6.53	6.90	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.24	2.00	5.59	6.76	[0 - 30]
dividendYielPercentageTTM	2.79	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.10	2.00	4.97	9.93	[0 - 30]
payoutRatioTTM	1.230	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	9.20	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.275	1.000	5.63	0	[0.1 - 0.5]
Total Score				7.12

Amgen Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.